The purpose of this study is to assess the drug levels of BMS-986196 and to evaluate the effect of food (fasted versus fed \[high-fat meal\]) on the drug levels after administration of BMS-986196 tablet formulation at two dose levels in healthy adult participants.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Specified dose on specified days
Area under the serum concentration-time curve from time zero to time of last quantifiable concentration (AUC [0-T])
Time frame: Predose and post-dose up to Day 10
Maximum observed serum concentration (Cmax)
Time frame: Predose and post-dose up to Day 10
Time of Cmax (Tmax)
Time frame: Predose and post-dose up to Day 10
Number of participants with adverse events (AEs)
Time frame: Up to Day 36
Number of participants with serious AEs (SAEs)
Time frame: Up to Day 36
Number of participants with vital sign abnormalities
Time frame: Up to Day 11
Number of participants with electrocardiogram (ECG) abnormalities
Time frame: Up to Day 11
Change from baseline in columbia-suicide severity rating scale (C-SSRS) at day 11
Time frame: Baseline, Day 11
Number of participants with physical examination findings
Time frame: Up to Day 11
Number of participants with clinical laboratory abnormalities
Time frame: Up to Day 11
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.